DWTX Dogwood Therapeutics, Inc.

Nasdaq dwtx.com


$ 5.75 $ -0.25 (-4.16 %)    

Friday, 17-Oct-2025 15:32:27 EDT
QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ 5.76
$ 5.95
$ 5.14 x 3
$ 6.25 x 35
$ 5.75 - $ 6.02
$ 1.62 - $ 29.28
22,456
na
11.01M
$ 2.26
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-13-2025 06-30-2025 10-Q
2 05-09-2025 03-31-2025 10-Q
3 03-31-2025 12-31-2024 10-K
4 11-08-2024 09-30-2024 10-Q
5 08-09-2024 06-30-2024 10-Q
6 05-10-2024 03-31-2024 10-Q
7 03-01-2024 12-31-2023 10-K
8 11-13-2023 09-30-2023 10-Q
9 08-11-2023 06-30-2023 10-Q
10 05-12-2023 03-31-2023 10-Q
11 03-14-2023 12-31-2022 10-K
12 11-14-2022 09-30-2022 10-Q
13 08-12-2022 06-30-2022 10-Q
14 05-13-2022 03-31-2022 10-Q
15 03-18-2022 12-31-2021 10-K
16 11-12-2021 09-30-2021 10-Q
17 08-13-2021 06-30-2021 10-Q
18 05-14-2021 03-31-2021 10-Q
19 03-23-2021 12-31-2020 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Dogwood Therapeutics, Inc. (NASDAQ:DWTX) (the "Company"), a development-stage biotechnology company developing new medi...

Core News & Articles

HC Wainwright & Co. analyst Sean Lee maintains Dogwood Therapeutics (NASDAQ:DWTX) with a Buy and raises the price target...

Core News & Articles

Gainers cbdMD (AMEX:YCBD) shares rose 116.3% to $1.35 during Monday's regular session. The company's market cap stands...

Core News & Articles

Gainers Dogwood Therapeutics (NASDAQ: DWTX) stock moved upwards by 80.1% to $9.94 during Monday's pre-market session. The ...

Core News & Articles

LRMR: -53% | Larimar shares are trading lower after the company reported seven patients experienced anaphylaxis and were withdr...

Core News & Articles

Dogwood Therapeutics (NASDAQ:DWTX) reported quarterly losses of $(1.99) per share which missed the analyst consensus estimate o...

Core News & Articles

- Halneuron® Chemotherapy-Induced Neuropathic Pain ("CINP") Phase 2b study interim data readout remains on track as pro...

Core News & Articles

-SEC Filing

Core News & Articles

Dogwood Therapeutics (NASDAQ:DWTX) reported quarterly losses of $(8.45) per share which missed the analyst consensus estimate o...

Core News & Articles

HC Wainwright & Co. analyst Sean Lee upgrades Dogwood Therapeutics (NASDAQ:DWTX) from Neutral to Buy and announces $10 p...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION